Alterity Therapeutics
Open
$4.39
Prev. Close
$4.39
High
$4.55
Low
$4.39
Market Snapshot
$84.88M
-8.60
$10.74M
9
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 9 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The firm is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 9 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The firm is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Recently from Cashu
FDA Approves Phase 3 Trial Design for Alterity Therapeutics’ Drug ATH434 in Rare Disease
Alterity Therapeutics (Ticker: ATHE) has made significant progress with its lead drug, ATH434, targeting a rare neuromuscular disorder. Recently, the U.S. Food and Drug Administration (FDA) approved k…
Alterity Therapeutics Advances Innovative Treatments for Neurodegenerative Diseases with PBT2
Alterity Therapeutics Seeks to Enhance Neurodegenerative Disease Treatments Through Innovative Approaches Alterity Therapeutics, a clinical-stage biotechnology company, focuses on developing novel the…
Alterity Therapeutics Advances ATH-1017 for Neurodegenerative Disease Treatment and Research Expansion
Alterity Therapeutics Advances in Neurodegenerative Disease Treatment Alterity Therapeutics makes significant strides in the treatment of neurodegenerative diseases, particularly focusing on alpha-syn…
Alterity Therapeutics Advances PBT434 in Neurodegenerative Disease Research and Treatment
Alterity Therapeutics Advances in Neurodegenerative Disease Research Alterity Therapeutics, a clinical-stage biotechnology company, focuses on developing innovative therapies for neurodegenerative dis…